CONMED Corporation Reports Third Quarter 2026 Financial Results; Updates Full Year 2026 Guidance

Patrick J. Beyer, President and Chief Executive Officer of CONMED

“Our third quarter organic, constant currency net sales growth was consistent with our expectations and our adjusted diluted EPS exceeded them, reflecting our team’s strong execution.”

Patrick J. Beyer, President and Chief Executive Officer of CONMED

“Importantly, our net sales growth on an organic, constant currency basis included balanced contributions from both our Orthopedic and General Surgery product lines, which were in turn powered by commercial traction across our key product growth platforms: AirSeal, Buffalo Filter, and BioBrace.”

Patrick J. Beyer, President and Chief Executive Officer of CONMED

“Our updated full year guidance reflects this strong performance in the third quarter and our latest outlook as we close out the year.”

Patrick J. Beyer, President and Chief Executive Officer of CONMED

“Looking ahead, our global team remains focused on executing our growth strategy to expand awareness and adoption of our key product platforms across the minimally invasive surgery, smoke evacuation, and orthopedic soft tissue repair markets.”

Patrick J. Beyer, President and Chief Executive Officer of CONMED

“With a sharpened strategic focus on these key markets following our recent portfolio optimization activities, CONMED is better positioned to support our customers, expand our market share, and drive both long-term growth and value creation going forward.”